Home > News > Altair Nanotechnologies Announces New Preclinical Testing
February 5th, 2004
Altair Nanotechnologies Announces New Preclinical Testing
Abstract:
Altair Nanotechnologies, Inc., a developer and manufacturer of innovative nanomaterial products, announced that it is planning to conduct new preclinical testing of its drug candidate, RenaZorb. The test will use an animal model directly comparing RenaZorb with existing and proposed drugs for phosphate control in patients with End Stage Renal Disease undergoing dialysis. The testing is expected to be initiated within 30 to 45 days. The company also announced that it plans to file an IND application with the U.S. Food and Drug Administration.
Source:
MarketWIre
Bookmark:
| Related News Press |
Nanomedicine
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes April 25th, 2025
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||